State of Wisconsin Investment Board Sells 33,474 Shares of Johnson & Johnson $JNJ

Key Points

• State of Wisconsin Investment Board trimmed its Johnson & Johnson stake by 2.6% in the fourth quarter, selling 33,474 shares and leaving it with 1,252,970 shares valued at about $259.3 million.
• Johnson & Johnson continues to draw investor attention from other institutions, while insiders also moved shares: EVP Kathryn E. Wengel sold 10,000 shares in June for about $2.41 million.
• The company’s fundamentals and outlook remain solid, with Q1 earnings and revenue topping estimates, a recent dividend increase to $1.34 per share, and analysts maintaining a Moderate Buy consensus with a $253.04 target price.

State of Wisconsin Investment Board decreased its holdings in Johnson & Johnson (NYSE:JNJ - Free Report) by 2.6% in the 4th quarter, according to the company in its most recent 13F filing with the SEC. The fund owned 1,252,970 shares of the company's stock after selling 33,474 shares during the quarter. Johnson & Johnson makes up about 0.6% of State of Wisconsin Investment Board's investment portfolio, making the stock its 18th largest position. State of Wisconsin Investment Board owned approximately 0.05% of Johnson & Johnson worth $259,302,000 at the end of the most recent quarter.

Other institutional investors and hedge funds also recently made changes to their positions in the company. Greenberg Financial Group acquired a new position in Johnson & Johnson in the fourth quarter valued at about $954,000. Mitsubishi UFJ Asset Management Co. Ltd. grew its stake in Johnson & Johnson by 4.3% in the third quarter. Mitsubishi UFJ Asset Management Co. Ltd. now owns 5,030,835 shares of the company's stock valued at $932,835,000 after acquiring an additional 208,765 shares during the period. JT Stratford LLC grew its stake in Johnson & Johnson by 7.6% in the third quarter. JT Stratford LLC now owns 59,577 shares of the company's stock valued at $11,047,000 after acquiring an additional 4,216 shares during the period. World Investment Advisors boosted its position in shares of Johnson & Johnson by 19.6% during the fourth quarter. World Investment Advisors now owns 161,343 shares of the company's stock worth $33,390,000 after buying an additional 26,450 shares during the period. Finally, Coldstream Capital Management Inc. boosted its position in shares of Johnson & Johnson by 9.8% during the third quarter. Coldstream Capital Management Inc. now owns 95,662 shares of the company's stock worth $17,738,000 after buying an additional 8,533 shares during the period. Institutional investors own 69.55% of the company's stock.

Key Johnson & Johnson News

Here are the key news stories impacting Johnson & Johnson this week:

• Positive Sentiment: Johnson & Johnson announced a more than $1 billion investment to expand U.S. Vision manufacturing in Jacksonville, Florida, adding new packaging, distribution, and advanced manufacturing capacity. The move supports its long-term manufacturing push and could improve supply-chain resilience. Article Title
• Positive Sentiment: J&J’s rare-disease drug IMAAVY (nipocalimab) posted strong Phase 2/3 results in warm autoimmune hemolytic anemia and received FDA Priority Review, reinforcing the company’s pipeline growth story. Article Title
• Positive Sentiment: TipRanks highlighted Johnson & Johnson as one of three dividend aristocrats with a Strong Buy rating, which may support investor interest in the stock’s defensive income profile. Article Title
• Neutral Sentiment: Analyst commentary noted JNJ’s strong recent share performance and asked whether the stock still offers value after a big one-year run, suggesting valuation concerns may be tempering upside.
• Negative Sentiment: Wall Street reacted to late-stage TALVEY blood-cancer trial results, with the article framing the data as important for whether J&J can keep growing after losing a multibillion-dollar drug, making the readout a potential pressure point for the stock. Article Title

Insider Buying and Selling at Johnson & Johnson

In other news, EVP Kathryn E. Wengel sold 10,000 shares of the stock in a transaction that occurred on Thursday, June 11th. The stock was sold at an average price of $241.15, for a total transaction of $2,411,500.00. Following the transaction, the executive vice president owned 114,288 shares in the company, valued at approximately $27,560,551.20. This trade represents a 8.05% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Company insiders own 0.16% of the company's stock.

Johnson & Johnson Stock Performance

JNJ opened at $235.29 on Wednesday. Johnson & Johnson has a 12-month low of $149.04 and a 12-month high of $251.71. The stock has a market cap of $566.40 billion, a price-to-earnings ratio of 27.20, a PEG ratio of 2.31 and a beta of 0.26. The business has a 50 day moving average of $231.22 and a 200-day moving average of $227.75. The company has a quick ratio of 0.77, a current ratio of 1.03 and a debt-to-equity ratio of 0.46.

Johnson & Johnson (NYSE:JNJ - Get Free Report) last released its quarterly earnings data on Tuesday, April 14th. The company reported $2.70 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $2.68 by $0.02. The company had revenue of $24.06 billion during the quarter, compared to analysts' expectations of $23.60 billion. Johnson & Johnson had a return on equity of 32.60% and a net margin of 21.83%.The business's revenue was up 9.9% on a year-over-year basis. During the same period last year, the firm posted $2.77 earnings per share. Johnson & Johnson has set its FY 2026 guidance at 11.450-11.650 EPS. On average, equities research analysts expect that Johnson & Johnson will post 11.57 earnings per share for the current year.

Johnson & Johnson Increases Dividend

The company also recently announced a quarterly dividend, which was paid on Tuesday, June 9th. Stockholders of record on Tuesday, May 26th were paid a dividend of $1.34 per share. This represents a $5.36 dividend on an annualized basis and a dividend yield of 2.3%. This is an increase from Johnson & Johnson's previous quarterly dividend of $1.30. The ex-dividend date was Tuesday, May 26th. Johnson & Johnson's dividend payout ratio is 61.97%.

Wall Street Analyst Weigh In

Several research firms have recently weighed in on JNJ. TD Cowen began coverage on Johnson & Johnson in a research report on Wednesday, April 8th. They set a "buy" rating and a $250.00 price objective for the company. HSBC upped their price objective on Johnson & Johnson from $265.00 to $280.00 and gave the stock a "buy" rating in a research report on Tuesday, March 17th. Raymond James Financial upped their price objective on Johnson & Johnson from $237.00 to $258.00 and gave the stock an "outperform" rating in a research report on Wednesday, April 15th. Weiss Ratings cut Johnson & Johnson from a "buy (b)" rating to a "buy (b-)" rating in a research report on Monday. Finally, Leerink Partners raised Johnson & Johnson from a "market perform" rating to an "outperform" rating and set a $265.00 price objective for the company in a research report on Wednesday, May 13th. Twenty analysts have rated the stock with a Buy rating and seven have assigned a Hold rating to the company. According to data from MarketBeat.com, Johnson & Johnson has an average rating of "Moderate Buy" and a consensus target price of $253.04.

Johnson & Johnson Company Profile

Johnson & Johnson is a multinational healthcare company headquartered in New Brunswick, New Jersey, that develops, manufactures and markets a broad range of products across pharmaceuticals, medical devices and previously consumer health. Founded in 1886 by the Johnson family, the company has grown into a global healthcare organization with operations and sales in many countries around the world.

The company's pharmaceuticals business, organized largely under its Janssen research and development organization, focuses on prescription medicines across therapeutic areas such as immunology, infectious disease, oncology and neuroscience.

Want to see what other hedge funds are holding JNJ? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Johnson & Johnson (NYSE:JNJ - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.